In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells.

Fusion oncogenes (FOs) are common in many cancer types and are powerful drivers of tumor development. Because their expression is exclusive to cancer cells and their elimination induces cell apoptosis in FO-driven cancers, FOs are attractive therapeutic targets. However, specifically targeting the resulting chimeric products is challenging. Based on CRISPR/Cas9 technology, here we devise a simple, efficient and non-patient-specific gene-editing strategy through targeting of two introns of the genes involved in the rearrangement, allowing for robust disruption of the FO specifically in cancer cells. As a proof-of-concept of its potential, we demonstrate the efficacy of intron-based targeting of transcription factors or tyrosine kinase FOs in reducing tumor burden/mortality in in vivo models. The FO targeting approach presented here might open new horizons for the selective elimination of cancer cells.

[Formal quality assessment of informed consent documents in 9 hospitals]. / Evaluación de la calidad formal de los documentos de consentimiento informado en 9 hospitales.

INTRODUCTION: Informed consent forms are very important in the process of medical information. The aim of this study is to design reliable formal quality criteria of these documents and their application in the evaluation of those used in the hospitals of a regional health service. MATERIAL AND METHODS: Criteria have been designed from the analysis of existing regulations, previous studies and consultation with key experts. The interobserver concordance was assessed using the kappa index. Criteria evaluation was performed on 1425 documents of 9 hospitals. RESULTS: A total of 19 criteria used in the evaluation of the quality of informed consent forms have been obtained. Kappa values were higher than 0,60 in 17 of them and higher than 0,52 in the other 2. The average number of defects per document was 7.6, with a high-low ratio among hospitals of 1.84. More than 90% of the documents had defects in the information on consequences and contraindications, and in about 90% it did not mention the copy to the patient. More than 60% did not comply with stating the purpose of the procedure, a statement of having understood and clarified doubts, and the treatment options. CONCLUSIONS: A tool has been obtained to reliably assess the formal quality of the informed consent forms. The documents assessed have a wide margin for improvement related to giving a copy to the patient, and some aspects of the specific information that patients should receive.

Changes in the density and localisation of endothelin receptors in the early stages of rat diabetic retinopathy and the effect of insulin treatment.

AIMS/HYPOTHESIS: The endothelin system (ET system) has been implicated in the retinal blood flow abnormalities that precede the onset of diabetic retinopathy. This study was undertaken to assess whether the density and localisation of both the immunoreactive endothelin-1 and endothelin receptors in rat retina change in the early stages of diabetes and the insulin treatment would affect those changes. METHODS: Untreated streptozotocin-diabetic, insulin-treated streptozotocin-diabetic and age-matched control rats were killed 15, 45 and 90 days after the induction of diabetes. Binding assays were used to determine the density and proportion of endothelin receptors in neural retinal membranes. Localisation of endothelin receptors and immunoreactive endothelin-1 were analysed by microautoradiography and immunohistochemistry, respectively. RESULTS: Fifteen days after the induction of diabetes, the neural retinal membranes of untreated streptozotocin-diabetic rats showed a statistically significant decrease in the density of both endothelin receptor subtypes when compared with age-matched control rats. At 90 days, however, the density of endothelin receptors type B was statistically significantly higher than that of control rats, and the innermost layers of the diabetic retina also showed an increase of both endothelin receptor type B receptor and immunoreactive endothelin-1 signal. Insulin treatment during 90 days up-regulated endothelin receptor type A in neural retinal membranes and in the innermost layers of the retina when compared with control retinas. CONCLUSION/INTERPRETATION: These results show that the endothelin system is altered in both vascular and neuronal components of the retina in early diabetic retinopathy. The up-regulation of endothelin receptor type A induced by insulin treatment suggests that insulin might be involved in retinal microangiopathy.

Effect of aging on optic nerve appearance: a longitudinal study.

AIM: To determine whether aging causes detectable changes in the appearance of the optic disc. METHODS: A retrospective longitudinal study was performed with quantitative and qualitative evaluations of digitised stereoscopic optic disc photographs of 224 eyes of 224 subjects. There were three groups: 100 normal subjects from the Framingham Eye Study, 68 glaucomatous patients followed longitudinally, and 56 normal subjects and glaucoma patients who had separate sets of disc photos taken on the same day. A disc was considered qualitatively worse if two of three experienced observers agreed that it was worse. Quantitative progression was defined as a >10% decrease in rim/disc area ratio measured with computer assisted planimetry. RESULTS: With quantitative evaluation, normal eyes (mean follow up 13 years) and same day eyes displayed no statistically significant difference in change of rim/disc area ratios (p=0.095), nor in the number of discs that progressed-five of 100 (5%) v two of 56 (4%) respectively. Glaucomatous eyes (mean follow up 9 years) showed a quantitative loss of disc rim in 24 of 68 (35%), and differed significantly from the normal eyes both in the change of rim/disc area ratio (p<0.0005) and number of discs that progressed (p<0.0005). With qualitative evaluation, the number of progressive discs in the glaucomatous eyes (31%) differed significantly (p<0. 0005) from the normal eyes (3%) and the same day eyes (0%). CONCLUSIONS: Over a period of follow up appropriate for long term outcome studies in glaucoma, there was no quantitatively or qualitatively detectable neuroretinal rim loss in normal aging optic nerves with stereoscopic optic disc photographs.

Type B and type C natriuretic peptide receptors modulate intraocular pressure in the rabbit eye.

We investigated (1) the in vivo functional significance of the type B (ANP(B)) and type C (ANP(C)) natriuretic peptide receptors in the rabbit eye by evaluating the effect of intracameral administration of C-type natriuretic peptide (CNP) and C-ANP-(4-23) on intraocular pressure, and (2) the action of CNP on guanylate cyclase activity in the rabbit ciliary process membranes. Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were also studied for comparison. We demonstrated that the natriuretic peptides decrease intraocular pressure and stimulate guanylate cyclase activity, CNP being the most potent. The duration of the effect of C-ANP-(4-23) on intraocular pressure reduction was almost 9-fold that of the BNP and 20-fold that of ANP and CNP effect. This ligand increased threefold the immunoreactive natriuretic peptides levels in aqueous humour. Our data demonstrate the presence of functional ANP(A) and ANP(B) receptors in the rabbit eye and that the ANP(C) receptor modulates the concentration of the natriuretic peptides in the aqueous humour.

Identification of endothelin receptor subtypes in rat ciliary body using subtype-selective ligands.

The endothelins are important vasoactive ocular peptides and there is some evidence that they may modulate intraocular pressure. We investigated the existence and localization of endothelin receptor subtypes using subtype selective ligands in rat ciliary body. Scatchard transformation of saturation binding experiments revealed that the KD and Bmax for [125I]ET-1 and [125I]ET-3 to membranes from ciliary body were 41.7+/-9 pM and 236+/-20 fmol mg-1 protein and 37. 8+/-0.4 pM and 160+/-2.0 fmol mg-1 protein, respectively. Competitive experiments in the presence of cyclic pentapeptide BQ123 (selective for ETA receptors) and BQ3020 (selective for ETB receptors), demonstrated the existence of ETA and ETB receptors in a ratio of 35:65. Cross-linking of [125I]ET-1 and [125I]ET-3 to ciliary body membranes resulted in the labeling of two bands with apparent molecular masses of 52 and 34 kDa, suggesting that ETA and ETB receptors have similar molecular mass. The 34 Kda band is a proteolytic degradation product of the 52 Kda band. Autoradiographic results show that specific [125I]ET-1 binding sites, displaced by BQ123 and BQ3020, are localized to the ciliary epithelium, supporting the idea that ETA and ETB subtype receptors exist in this tissue.

Higher proportions of type C than of types A and B natriuretic peptide receptors exist in the rat ciliary body.

We investigate the interaction of atrial natriuretic peptide (ANP) brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) with their receptors (NPRA, NPRB and NPRC), as well as the proportion and localization of those receptors in the rat ciliary body. Binding assays and affinity cross-linking experiments demonstrated the presence of the NPRC receptor type. However, the three natriuretic peptides stimulate the guanylate cyclase activity in the ciliary body membranes suggesting the presence of the NPRA and NPRB receptor type. Microautoradiographic data show that the NPRs are localized in the whole ciliary body. Our results indicated that NPRC is the most prominent receptor type in this tissue.

Identification of endothelin receptor subtypes in rat retina using subtype-selective ligands.

We investigate the existence of endothelin receptor subtypes using subtype selective ligands and the presence of immunoreactive (IR) endothelin (ET)-3 (IR-ET-3) by radioimmunoassay (RIA) in rat retina. Scatchard transformation of saturation binding experiments with [125I]ET-3 revealed specific binding sites with a Kd and Bmax values of 42 +/- 12 pM and 111 +/- 24 fmol/mg of protein, respectively. The Kd was similar to that obtain in previous studies using [125I]ET-1. However, the Bmax was 65% of that obtained with [125I]ET-1. Competitive experiments in the presence of the cyclic pentapeptide BQ123 (selective for ETA receptor) and Sarafotoxin 6C (selective for ETB receptor), demonstrated the existence of ETA and ETB receptors in a ratio of 35:65. The order of potency of ET family peptides was ET-3 = ET-1 > S6C for ETB receptor and ET-1 > ET-3 > BQ123 for ETA receptor. Cross-linking of [125I]ET-1 to retinal membranes with disuccinimidyl suberate and SDS-PAGE followed by autoradiography resulted in the labeling of two bands with apparent molecular masses of 52 and 34 kDa. Similar results were obtained using [125I]ET-3, suggesting that ETA and ETB receptors have similar molecular mass. The 34 kDa band is a proteolytic degradation product of the 52 kDa band. The concentration of IR-ET-3 was 1212 +/- 153 fmol/g wet weight in rat retina. All these data suggest that ETs may play a role in neurotransmission or neuromodulation in the retina, operating on both ETA and ETB receptor subtypes present in this tissue.

Identification of endothelin receptor subtype (ETB) in human cerebral cortex using subtype-selective ligands.

Specific endothelin (ET) binding sites were characterized in membranes prepared from human cerebral cortices using binding assay and cross-linking analysis. The presence of immunoreactive (IR) ET-1 was studied by radioimmunoassay. Saturation binding experiments revealed that the KD and Bmax for 125I-ET-1 and 125I-ET-3 to membranes from gray matter were 25 +/- 6 pM and 115 +/- 15 fmol/mg of protein and 24 +/- 5 pM and 108 +/- 13 fmol/mg of protein, respectively. Similar results were obtained for white matter. In the presence of 10 nM sarafotoxin-6c, which is selective for ETB receptors, 125I-ET-1 and 125I-ET-3 binding was totally abolished. However, in the presence of 1 microM BQ123, which is selective for ETA receptors, both bindings were not affected. These results suggest that the human cerebral cortex contains only ETB receptors. Cross-linking of 125I-ET-1 and 125I-ET-3 to membranes with disuccinimidyl suberate resulted in the labeling of two bands of 48 and 31 kDa. Concentrations of IR-ET-1 in the gray and white matter were 7.0 +/- 3.2 and 2.5 +/- 1.7 fmol/g wet weight, respectively. The demonstration of high-affinity ETB receptors and the presence of IR-ET-1 suggest that the peptide may act as a neurotransmitter or neuromodulator in the human cerebral cortex.

Identification and characterization of endothelin receptor subtype B in rat retina.

The presence of immunoreactive (IR) endothelin (ET)-1 and ET-1 receptors in rat retina has been studied by radioimmunoassay and receptor assay, respectively. The specific binding of 125I-ET-1 to rat retinal particulate preparations was saturable. Apparent equilibrium conditions were established within 120-140 min. Scatchard analysis of binding data indicated a single class of high-affinity binding sites with a KD of 35 +/- 11 pM and a Bmax of 168 +/- 60 fmol/mg of protein. 125I-ET-1 binding to retinal particulate preparations was not inhibited by 1 microM concentrations of somatostatin, atrial natriuretic factor, brain natriuretic peptide, thyroid-stimulating hormone, growth hormone, or insulin. The three endothelin isoforms, ET-1, -2, and -3, had similar affinity for the receptor. Cross-linking of 125I-ET-1 to retinal particulate preparations with disuccinimidyl suberate resulted in the labeling of two bands with apparent molecular masses of 52 and 34 kDa. We have established a highly sensitive and specific radioimmunoassay for ET-1. The concentration of IR-ET-1 in rat retina was 35 +/- 10 fmol/g wet weight. The demonstration of specific high-affinity ETB receptors and the presence of IR-ET-1 suggest that the peptide may act as a neurotransmitter or neuromodulator in the retina.